State of Alaska Department of Revenue Sells 28,470 Shares of Kenvue Inc. (NYSE:KVUE)

State of Alaska Department of Revenue decreased its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 11.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 218,585 shares of the company's stock after selling 28,470 shares during the quarter. State of Alaska Department of Revenue's holdings in Kenvue were worth $4,666,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Grove Bank & Trust increased its stake in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Kenvue in the 4th quarter valued at $29,000. Riverview Trust Co acquired a new position in Kenvue in the 3rd quarter valued at $30,000. Fortitude Family Office LLC grew its stake in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after buying an additional 777 shares during the last quarter. Finally, Ashton Thomas Securities LLC acquired a new position in Kenvue in the 3rd quarter valued at $35,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on KVUE shares. Citigroup lowered their target price on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 15th. Canaccord Genuity Group lowered their target price on shares of Kenvue from $27.00 to $24.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Bank of America raised their target price on shares of Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, October 22nd. Piper Sandler raised shares of Kenvue from a "neutral" rating to an "overweight" rating and increased their price target for the company from $21.00 to $26.00 in a report on Monday, January 6th. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $23.00.

Kenvue Trading Up 0.2 %

Shares of NYSE:KVUE traded up $0.05 during trading on Wednesday, hitting $20.96. 10,316,961 shares of the company's stock were exchanged, compared to its average volume of 12,673,827. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The firm has a 50-day moving average price of $21.41 and a two-hundred day moving average price of $22.03. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market cap of $40.19 billion, a P/E ratio of 39.55, a PEG ratio of 2.16 and a beta of 1.45.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities analysts predict that Kenvue Inc. will post 1.05 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.91%. The ex-dividend date is Wednesday, February 12th. Kenvue's dividend payout ratio is currently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.